International experience of using olaparib for metastatic castration-resistant prostate cancer: literature review

被引：0
|
作者：
Matveev, V. B. [1 ]
Khalmurzaev, O. A. [1 ]
Evsyukova, O., I [1 ]
机构：
[1] Minist Hlth Russia, NN Blokhin Natl Med Res Ctr Oncol, 24 Kashirskoe Shosse, Moscow 115478, Russia
来源：
ONKOUROLOGIYA | 2020年 / 16卷 / 04期
关键词：
prostate cancer; HRR mutations; BRCA; olaparib; DNA-REPAIR;
D O I：
10.17650/1726-9776-2020-16-4-197-206
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The following review presents a problem of metastatic castration-resistant prostate cancer and its association with germline or somatic mutations in homologous recombination repair (HRR). In 2020, olaparib was approved in the Russian Federation as a monotherapy for metastatic castration-resistant prostate cancer with germline or somatic mutations of genes involved in DNA repair by homologous recombination, after progression on therapy with new hormonal drugs. We describe a review of the main olaparib clinical trials assessing its efficacy, safety and tolerance in metastatic castration-resistant prostate cancer patients.
引用
收藏
页码：197 / 206
页数：10
相关论文
共 50 条
  • [31] Olaparib for Chinese metastatic castration-resistant prostate cancer: A real-world study of efficacy and gene predictive analysis
    Baijun Dong
    Bin Yang
    Wei Chen
    Xinxing Du
    Liancheng Fan
    Xudong Yao
    Wei Xue
    Medical Oncology, 39
  • [32] Metastatic castration-resistant prostate cancer and PARP inhibitors: From tumor genomics to new therapeutic combinations
    Oudard, Stephane
    Timsit, Marc-Olivier
    Maillet, Denis
    Mouillet, Guillaume
    Campedel, Luca
    Colomba, Emeline
    Dourthe, Louis Marie
    Eymard, Jean-Christophe
    Gobert, Aurelien
    Jamet, Claire
    Joly, Charlotte
    Serrate, Camille
    Ploussard, Guillaume
    BULLETIN DU CANCER, 2025, 112 (01) : 61 - 81
  • [33] A Narrative Review of Implementing Precision Oncology in Metastatic Castration-Resistant Prostate Cancer in Emerging Countries
    Bazarbashi, Shouki
    Su, Wen-Pin
    Wong, Siew W.
    Singarachari, Ramanujam A.
    Rawal, Sudhir
    Volkova, Maria I.
    Bastos, Diogo A.
    ONCOLOGY AND THERAPY, 2021, 9 (02) : 311 - 327
  • [34] HTA and Reimbursement Status of Metastatic Hormone-Sensitive Prostate Cancer, Nonmetastatic Castration-Resistant Prostate Cancer, and Metastatic Castration-Resistant Prostate Cancer Treatments in Europe: A Patient Access Landscape Review
    Bencina, Goran
    Petrova, Elina
    Sonmez, Demet
    Pereira, Sonia Matos
    Dimitriadis, Ioannis
    Salomonsson, Stina
    JOURNAL OF HEALTH ECONOMICS AND OUTCOMES RESEARCH, 2023, 10 (01): : 102 - 110
  • [35] Circulating Tumor Cells in Metastatic Castration-Resistant Prostate Cancer
    Rini, Brian I.
    CURRENT ONCOLOGY REPORTS, 2009, 11 (03) : 163 - 164
  • [36] Targeting the androgen receptor in metastatic castration-resistant prostate cancer
    Aragon-Ching, Jeanny B.
    FUTURE ONCOLOGY, 2014, 10 (03) : 329 - 332
  • [37] Optimal Therapy Sequencing in Metastatic Castration-Resistant Prostate Cancer
    Sausan Abouharb
    Paul G. Corn
    Current Oncology Reports, 2013, 15 : 217 - 223
  • [38] Optimal Treatment Sequence for Metastatic Castration-resistant Prostate Cancer
    Lorente, David
    Fizazi, Karim
    Sweeney, Christopher
    de Bono, Johann S.
    EUROPEAN UROLOGY FOCUS, 2016, 2 (05): : 488 - 498
  • [39] The role of cabazitaxel in the treatment of metastatic castration-resistant prostate cancer
    Tsao, Che-Kai
    Cutting, Elena
    Martin, Jacob
    Oh, William K.
    THERAPEUTIC ADVANCES IN UROLOGY, 2014, 6 (03) : 97 - 104
  • [40] Optimal Therapy Sequencing in Metastatic Castration-Resistant Prostate Cancer
    Abouharb, Sausan
    Corn, Paul G.
    CURRENT ONCOLOGY REPORTS, 2013, 15 (03) : 217 - 223
12345